Charles B Nguyen
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charles B Nguyen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07218692 · RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyCity of Hope Medical Center · withdrawn · Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2004 to 2026Named on NCT07218692
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:00 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.Clin Cancer Res · 202437 citationsRCR 3.8
- Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.Ann Neurol · 201630 citationsRCR 1.2
- A Time and Motion Study of Pharmacists and Pharmacy Technicians Obtaining Admission Medication Histories.J Hosp Med · 201719 citationsRCR 1.5
- Symptoms associated with oophorectomy and tamoxifen treatment for breast cancer in premenopausal Vietnamese women.Breast Cancer Res Treat · 19996 citationsRCR 0.2
- A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer.J Urol · 20234 citationsRCR 0.3
- Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).JCO Precis Oncol · 20252 citationsRCR 0.4